BridgeMD
New treatment option for Melanoma Stage III
Official title Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
ClinicalTrials.gov ID: NCT06508775
What this study is testing
What is MB-CART19.1?
MB-CART19.1 is an investigational medicine, being studied as a potential treatment for melanoma stage iii.
Also referred to as CD19-targeting CAR T cells, Anti-CD19 CAR T cells.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Adults
You may be able to join if
- Patient underwent treatment with a Miltenyi CAR T cell therapy in one of the parent trials at least 12 months prior to enrollment in long-term...
- Patient has provided informed consent prior to enrollment.
You likely can't join if
- No exclusion criteria
The study team makes the final eligibility decision.
Where it's taking place
- Berlin, Germany
- Cologne, Germany
- Erlangen, Germany
- Göttingen, Germany
- Münster, Germany
- Tübingen, Germany
- Würzburg, Germany
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, not specified. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Berlin, Germany; Cologne, Germany; Erlangen, Germany; Göttingen, Germany; Münster, Germany; Tübingen, Germany and 1 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.